Excellent news!
Ongoing work from companies like Bayer, certainly lift the profile of the company and also it provides regular income and cash flow.
I like below comment from Craig in today's announcement.
Hopefully working with partners and customers will add supporting evidence and validation capabilities of SphygmoCor to obtain regulatory clearance for the upcoming future products of the company. Just to remind everyone, Company is working on multiple new products and revenue streams on track for 2020/ 2021 (as mentioned in recent corporate presentation)
All in my opinion and research.
Good luck to all.
